These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1684153)

  • 1. Detection of DNA sequence polymorphisms in carcinogen metabolism genes by polymerase chain reaction.
    Bell DA
    Environ Mol Mutagen; 1991; 18(4):245-8. PubMed ID: 1684153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
    Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
    Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
    Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M
    Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase mu.
    Bell DA; Thompson CL; Taylor J; Miller CR; Perera F; Hsieh LL; Lucier GW
    Environ Health Perspect; 1992 Nov; 98():113-7. PubMed ID: 1486839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6.
    Heim MH; Meyer UA
    Methods Enzymol; 1991; 206():173-83. PubMed ID: 1686063
    [No Abstract]   [Full Text] [Related]  

  • 8. DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.
    Panserat S; Mura C; Gérard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
    Hum Genet; 1994 Oct; 94(4):401-6. PubMed ID: 7927337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.
    Smith CA; Moss JE; Gough AC; Spurr NK; Wolf CR
    Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 genes and risk of liver cancer.
    Agúndez JA; Ledesma MC; Benítez J; Ladero JM; Rodríguez-Lescure A; Díaz-Rubio E; Díaz-Rubio M
    Lancet; 1995 Apr; 345(8953):830-1. PubMed ID: 7898230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
    Mura C; Panserat S; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
    Hum Genet; 1993 Oct; 92(4):367-72. PubMed ID: 7901140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of debrisoquine hydroxylation phenotypes.
    Wolf CR; Moss JE; Miles JS; Gough AC; Spurr NK
    Lancet; 1990 Dec; 336(8728):1452-3. PubMed ID: 1978915
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
    Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR
    Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NcoI RFLP in the pseudogene (CYP2D8P) of the human debrisoquine 4-hydroxylase locus.
    Mura C; Broyart JP; Jacqz E; Elion J; Krishnamoorthy R
    Nucleic Acids Res; 1991 Mar; 19(5):1162. PubMed ID: 1673559
    [No Abstract]   [Full Text] [Related]  

  • 17. Debrisoquine hydroxylase gene polymorphism in meningioma.
    Wundrack I; Meese E; Müllenbach R; Blin N
    Acta Neuropathol; 1994; 88(5):472-4. PubMed ID: 7847077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility.
    Wolf CR; Smith CA; Gough AC; Moss JE; Vallis KA; Howard G; Carey FJ; Mills K; McNee W; Carmichael J
    Carcinogenesis; 1992 Jun; 13(6):1035-8. PubMed ID: 1600608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
    Nebert DW; McKinnon RA; Puga A
    DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.
    Løvlie R; Daly AK; Molven A; Idle JR; Steen VM
    FEBS Lett; 1996 Aug; 392(1):30-4. PubMed ID: 8769309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.